Kura Oncology is trading 6.9% lower at $7.08 amid a sharp broader-market sell-off. - The supplied market context shows major U.S. indexes lower, alongside biotech-sector weakness. - No clear company-specific announcement on November 5 explains the decline; the recent ASH presentations announcement is not reported as a catalyst.